Skip to main content
SpringerLink
Log in

Biapenem

  • Adis New Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

  • ▴ Biapenem is a new parenteral carbapenem antibacterial agent with a broad spectrum of in vitro antibacterial activity encompassing many Gramnegative and Gram-positive aerobic and anaerobic bacteria, including species producing β-lactamases.

  • ▴ Biapenem is more stable than imipenem, mero-penem and panipenem to hydrolysis by human renal dihydropeptidase-I (DHP-I), and therefore does not require the coadministration of a DHP-I inhibitor.

  • ▴ After intravenous administration, biapenem is widely distributed and penetrates well into various tissues (e.g. lung tissue) and body fluids (e.g. sputum, pleural effusion, abdominal cavity fluid).

  • ▴ In randomised, nonblind or double-blind clinical trials, biapenem showed good clinical and bacteriological efficacy (similar to that of imipenem/ cilastatin) in the treatment of adult patients with intra-abdominal infections, lower respiratory infections or complicated urinary tract infections.

  • ▴ Biapenem is generally well tolerated. The most common adverse events in clinical trials were skin eruptions/rashes, nausea and diarrhoea.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Yang Y, Testa RT, Bhachech N, et al. Biochemical characterization of novel tetrahydrofuranyl 1β- methylcarba-penems: stability to hydrolysis by renal dehydropeptidases and bacterial β-lactamases, binding to penicillin binding proteins, and permeability properties. Antimicrob Agents Chemother 1999 Dec; 43(12): 2904–9

    PubMed  CAS  Google Scholar 

  2. Felici A, Perilli M, Segatore B, et al. Interactions of biapenem with active-site serine and metallo-β- lactamases. Antimicrob Agents Chemother 1995 Jun; 39(6): 1300–5

    Article  PubMed  CAS  Google Scholar 

  3. Yang Y, Bhachech N, Bush K. Biochemical comparison of imipenem, meropenem and biapenem: permeability, binding to penicillin-binding proteins, and stability to hydrolysis by β-lactamases. J Antimicrob Chemother 1995 Jan; 35(1): 75–84

    Article  PubMed  CAS  Google Scholar 

  4. Ubukata K, Sugiura M, Konno M. In vitro activity of biapenem, a new carbapenem antibiotic [in Japanese]. Chemotherapy 1994; 42 Suppl. 4: 20–5

    Google Scholar 

  5. Kashitani F, Fukuzawa S, Mori C, et al. In vitro activities of carbapenem antibiotics against the various clinical isolates [abstract] [in Japanese]. Jpn J Antibot 2000 Jan; 53(1): 25

    Google Scholar 

  6. Ubukata K, Chiba N, Kobayashi R, et al. Comparison of in vitro activity of biapenem with other antimicrobial agents against clinical isolates of Pseudomonas aeruginosa. Chemother Jpn 2002 Jan; 50(1): 1–10

    CAS  Google Scholar 

  7. Hikida M, Kawashima K, Yoshida M, et al. Inactivation of new carbapenem antibiotics by dehydropeptidase-I from porcine and human renal cortex. J Antimicrob Chemother 1992 Aug; 30: 129–34

    Article  PubMed  CAS  Google Scholar 

  8. Hikida M, Kawashima K, Nishiki K, et al. Renal dehydropeptidase-I stability of LJC 10,627, a new carbapenem antibiotic. Antimicrob Agents Chemother 1992 Feb; 36(2): 481–3

    Article  PubMed  CAS  Google Scholar 

  9. Sader HS, Gales AC. Emerging strategies in infectious diseases: new carbapenem and trinem antibacterial agents. Drugs 2001; 61(5): 553–64

    Article  PubMed  CAS  Google Scholar 

  10. Day IP, Goudie J, Nishiki K, et al. Correlation between in vitro and in vivo models of proconvulsive activity with the carbapenem antibiotics, biapenem, imipenem/cilastatin and meropenem. Toxicol Lett 1995 Apr; 76(3): 239–43

    Article  PubMed  CAS  Google Scholar 

  11. Hikida M, Masukawa Y, Nishiki K, et al. Low neurotoxicity of LJC 10,627, a novel 1 beta-methyl carbapenem antibiotic: inhibition of gamma-aminobutyric acidA, benzodiazepine, and glycine receptor binding in relation to lack of central nervous system toxicity in rats. Antimicrob Agents Chemother 1993 Feb; 37(2): 199–202

    Article  PubMed  CAS  Google Scholar 

  12. Hori S, Kanemitsu K, Shimada J. Relation between convulsant activity of biapenem, a new carbapenem, and its binding affinity to GABA receptor [in Japanese]. Chemotherapy 1994; 42 Suppl. 4: 115–20

    Google Scholar 

  13. Hoban DJ, Jones RN, Yamane N, et al. In vitro activity of three carbapenem antibiotics. Comparative studies with biapenem (L-627), imipenem, and meropenem against aerobic pathogens isolated worldwide. Diagn Microbiol Infect Dis 1993 Nov 1993 31; 17(4): 299–305

    CAS  Google Scholar 

  14. Igari J, Inoue M, Nishino T, et al. Survey of sensitivities of clinical isolates to antibacterial agents (annual report) [in Japanese]. Jpn J Antibiot 1997 Aug; 50(8): 683–703

    PubMed  CAS  Google Scholar 

  15. Igari J, Watanabe N, Uehara N, et al. Changes in the antibacterial activity of chemotherapeutic agents (especially carbapenems) for 10 species of clinical isolates between 1994 and 1996. Surveillance group of the sensitivities of clinical isolates to antibacterial agents [in Japanese]. Jpn J Antibiot 2000 Mar; 53(3): 157–70

    CAS  Google Scholar 

  16. Watanabe A, Kikuchi H, Kikuchi T, et al. Comparative in vitro activity of carbapenem antibiotics against respiratory pathogens isolated in recent years. J Infect Chemother 1999 Sep; 5(3): 171–5

    Article  PubMed  CAS  Google Scholar 

  17. Suzuki Y, Nishinari C, Endo H, et al. Antimicrobial activities of carbapenems and forth generation cephems against clinically isolated strains [in Japanese]. Jpn J Antibiot 2001 Sep; 54(9): 473–90

    PubMed  CAS  Google Scholar 

  18. Catchpole CR, Wise R, Thornber D, et al. In vitro activity of L-627, a new carbapenem. Antimicrob Agents Chemother 1992 Sep; 36(9): 1928–34

    Article  PubMed  CAS  Google Scholar 

  19. Bonfiglio G, Maccarone G, Mezzatesta ML, et al. In vitro activity of biapenem against recent gram-negative and gram-positive clinical isolates. Chemotherapy 1997 Nov 31; 43(6): 393

    Article  PubMed  CAS  Google Scholar 

  20. Ubukata K, Hikida M, Yoshida M, et al. In vitro activity of LJC10,627, a new carbapenem antibiotic with high stability to dehydropeptidase I. Antimicrob Agents Chemother 1990 Jun; 34(6): 994–1000

    Article  PubMed  CAS  Google Scholar 

  21. Malanoski GJ, Collins L, Wennersten C, et al. In vitro activity of biapenem against clinical isolates of gram- positive and gram-negative bacteria. Antimicrob Agents Chemother 1993 Sep; 37(9): 2009–16

    Article  PubMed  CAS  Google Scholar 

  22. Neu HC, Gu JW, Fang W, et al. In vitro activity and beta-lactamase stability of LJC 10,627. Antimicrob Agents Chemother 1992 Jul; 36(7): 1418–23

    Article  PubMed  CAS  Google Scholar 

  23. Watanabe A, Tokue Y, Takahashi H, et al. In vitro activity of biapenem (BIPM) against clinically isolated respiratory pathogens in 1996–1998 [in Japanese]. Jpn J Antibiot 1999 Dec; 52(12): 690–4

    PubMed  CAS  Google Scholar 

  24. Yoshida M, Watanabe M, Mitsuhashi S. In vitro antibacterial activity of biapenem, a new carbapenem antibiotic [in Japanese]. Chemotherapy 1994; 42 Suppl. 4: 1–19

    Google Scholar 

  25. Raymond NJ, Bremner DA. The in-vitro activity of biapanem against 964 clinical isolates of aerobic bacteria. J Antimicrob Chemother 1995 May; 35(5): 681–6

    Article  PubMed  CAS  Google Scholar 

  26. Murase M. In vitro antibacterial activities of carbapenems against clinical isolates [in Japanese]. Jpn J Antibiot 1999 Nov; 52(11): 667–79

    PubMed  CAS  Google Scholar 

  27. Alonso R, Fernandez-Aranguiz A, Colom K, et al. In vitro activity of biapenem against beta-lactamase producing Enterobacteriaceae. Eur J Clin Microbiol Infect Dis 1994 Oct; 13(10): 820–2

    Article  PubMed  CAS  Google Scholar 

  28. Chen HY, Livermore DM. Comparative in-vitro activity of biapenem against enterobacteria with β-lactamase-mediated antibiotic resistance. J Antimicrob Chemother 1994 Mar; 33(3): 453–64

    Article  PubMed  CAS  Google Scholar 

  29. Watanabe A, Tokue Y, Takahashi H, et al. Comparative in-vitro activity of carbapenem antibiotics against respiratory pathogens isolated between 1999 and 2000. J Infect Chemother 2001 Dec; 7(4): 267–71

    Article  PubMed  CAS  Google Scholar 

  30. Fujiue Y, Kuwabara M, Muroki K, et al. The antimicrobial susceptibilities and serotypes of Pseudomonas aeruginosa isolated from sputum [in Japanese]. Jpn J Antibiot 1998 Jan; 51(1): 26–36

    Article  PubMed  CAS  Google Scholar 

  31. Hirakata Y, Matsuda J, Mochida C, et al. Annual changes is susceptibility of clinical isolates to biapenem [in Japanese]. Jpn J Chemother 2002; 50(6): 329–51

    Google Scholar 

  32. Chen HY, Livermore DM. In-vitro activity of biapenem, compared with imipenem and meropenem, against Pseudomonas aeruginosa strains and mutants with known resistance mechanisms. J Antimicrob Chemother 1994 May; 33(5): 949–58

    Article  PubMed  CAS  Google Scholar 

  33. Shibata K, Adachi Y, Kato E, et al. In vitro and in vivo evaluation of BO-2727 against imipenem- and/or meropenem-resistant Pseudomonas aeruginosa. J Antibiot (Tokyo) 1997 Feb; 50(2): 135–8

    Article  CAS  Google Scholar 

  34. Hikida M, Terashima S, Sato Y, et al. Comparative antibacterial activity of carbapenems againstP. aeruginosa (1) [in Japanese]. Jpn J Antibiot 2001 Nov; 54(11): 571–9

    PubMed  CAS  Google Scholar 

  35. Hikida M, Mori M, Kitta T. In vitro evaluation of biapenem, a new carbapenem antibiotic. Chemotherapy 1994 Dec; 42(S-4): 101

    Google Scholar 

  36. Simor AE, Louie L, Louie M. In vitro susceptibility of Acinetobacter baumannii to biapenem, piperacillin/ tazobactam and thirteen other antimicrobial agents [letter]. Eur J Clin Microbiol Infect Dis 1994 Jun; 13(6): 521–3

    Article  PubMed  CAS  Google Scholar 

  37. Clarke AM, Zemcov SJV. Comparative in vitro activity of biapenem, a new carbapenem antibiotic. Eur J Clin Microbiol Infect Dis 1993; 12(5): 377–84

    Article  PubMed  CAS  Google Scholar 

  38. Spangler SK, Jacobs MR, Appelbaum PC. Susceptibilities of 177 penicillin-susceptible and -resistant pneumococci to FK 037, cefpirome, cefepime, ceftriaxone, cefotaxime, ceftazidime, imipenem, biapenem, meropenem, and vancomycin. Antimicrob Agents Chemother 1994 Apr; 38(4): 898–900

    Article  PubMed  CAS  Google Scholar 

  39. Weiss WJ, Petersen PJ, Jacobus NV, et al. In vitro activities of aminomethyl-substituted analogs of novel tetrahydrofuranyl carbapenems. Antimicrob Agents Chemother 1999 Mar; 43(3): 454–9

    PubMed  CAS  Google Scholar 

  40. Chiba N, Kobayashi R, Hasegawa K. Activity of biapenem and 7 other antimicrobial agents against Streptococcus pneumoniae [in Japanese]. Jpn J Chemother 2002 Mar; 50(3): 161–70

    CAS  Google Scholar 

  41. Saito A, Inamatsu T, Okada T, et al. Committee Report: Clinical breakpoints in pulmonary infections and sepsis: new antimicrobial agents and supplemental information for some agents already released [in Japanese]. J Infect Chemother 1999; 5(4): 223–6

    Article  PubMed  CAS  Google Scholar 

  42. Aldridge KE, Morice N, Schiro DD. In vitro activity of biapenem (L-627), a new carbapenem, against anaerobes. Antimicrob Agents Chemother 1994 Apr; 38(4): 889–93

    Article  PubMed  CAS  Google Scholar 

  43. Garcia-Rodriguez JA, Garcia-Sanchez JE, Trujillano-Martin I, et al. L-627, a novel carbapenem: in-vitro activity against anaerobes [letter]. J Antimicrob Chemother 1994 Jan; 33(1): 183–6

    Article  PubMed  CAS  Google Scholar 

  44. Wexler HM, Molitoris E, Finegold SM. The in-vitro activity of L-627 against anaerobic bacteria. J Antimicrob Chemother 1994 Mar; 33(3): 629–34

    Article  PubMed  CAS  Google Scholar 

  45. Appelbaum PC, Spangler SK, Jacobs MR. Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam. J Antimicrob Chemother 1993 Aug; 32(2): 223–31

    Article  PubMed  CAS  Google Scholar 

  46. Nord CE, Lindmark A, Persson I. In vitro activity of L-627 against anaerobic bacteria. Eur J Clin Microbiol Infect Dis 1992 Aug; 11(8):757–60

    Article  PubMed  CAS  Google Scholar 

  47. Miyake Y, Fujiwara S, Usui T, et al. In vitro antibacterial activity of biapenem against adherent bacteria [in Japanese]. Chemotherapy 1994; 42 Suppl. 4: 82–90

    Google Scholar 

  48. Hiraishi T, Miyata A, Hara T, et al. Bactericidal activity of biapenem against various bacteria [in Japanese]. Jpn J Antibiot 2001 Dec; 54(12): 581–95

    PubMed  CAS  Google Scholar 

  49. Hiraishi T, Miyata A, Takata T. Bactericidal activity of biapenem against various efflux system mutants of Pseudomonas aeruginosa [in Japanese]. Jpn J Antibot 2002 Feb; 55(1): 76

    Google Scholar 

  50. Hikida M, Yamazaki Y, Yoshida M, et al. Postantibiotic effect of carbapenems against Pseudomonas aeruginosa. J Antibiot (Tokyo) 1995 Aug; 48(8): 891–2

    Article  CAS  Google Scholar 

  51. Houston AK, Jones RN. Post-antibiotic effect of FK-037 and biapenem tested against five bacterial species. J Chemother 1994 Feb; 6(1): 12–4

    PubMed  CAS  Google Scholar 

  52. Nakashima M, Uematsu T, Ueno K, et al. Phase 1 study of L-627, biapenem, a new parenteral carbapenem antibiotic. Int J Clin Pharmacol Ther Toxicol 1993 Feb; 31(2): 70–6

    PubMed  CAS  Google Scholar 

  53. Tarao F, Miura T, Saito A, et al. Pharmacokinetic study of biapenem [in Japanese]. Jpn J Chemother 1996; 44(10): 769–75

    CAS  Google Scholar 

  54. Nagashima S, Kozawa O, Otsuka T, et al. Pharmacokinetics of a parenteral carbapenem, biapenem, in patients with end-stage renal disease and influence of haemodialysis. J Anti-microb Chemother 2000 Nov; 46(5): 839–42

    CAS  Google Scholar 

  55. Kozawa O, Uematsu T, Matsuno H, et al. Pharmacokinetics and safety of a new parenteral carbapenem antibiotic, biapenem (L-627), in elderly subjects. Antimicrob Agents Chemother 1998 Jun; 42(6): 1433–6

    PubMed  CAS  Google Scholar 

  56. Meiji. Omegacin® (biapenem) prescribing information [in Japanese]. Kanagawa, Japan: Meiji, 2002

  57. Koeppe P, Hoffler D, Fitzen B. Biapenem pharmacokinetics in healthy volunteers and in patients with impaired renal function. Arzneimittelforschung 1997 Nov; 47(11): 1250–6

    PubMed  CAS  Google Scholar 

  58. Mori M, Hikida M, Nishihara T, et al. Comparative stability of carbapenem and penem antibiotics to human recombinant dehydro-peptidase-I. J Antimicrob Chemother 1996 May; 37: 1034–6

    Article  PubMed  CAS  Google Scholar 

  59. Brismar B, Akerlund JE, Sjostedt S, et al. Biapenem versus imipenem/cilastatin in the treatment of complicated intra-abdominal infections: report from a Swedish Study Group. Scand J Infect Dis 1996; 28(5): 507–12

    Article  PubMed  CAS  Google Scholar 

  60. Matsumoto F, Inoue M, Sakurai I, et al. Dose-comparison study on biapenem in the treatment of chronic bronchitis [in Japanese]. Jpn J Chemother 2000; 48(1): 34–44

    Google Scholar 

  61. Matsumoto F, Inoue M, Sakurai I, et al. A comparative study of biapenem and imipemem/cilastatin in lower respiratory infections [in Japanese]. Jpn J Chemother 2000; 48(1): 45–67

    Google Scholar 

  62. Matsumoto F, Imai T, Sakurai I, et al. A comparative study of biapenem and imipenem/cilastatin for chronic respiratory tract infection [in Japanese]. Jpn J Chemother 1995; 43(1): 63–84

    Google Scholar 

  63. Matsumoto F, Imai T, Sakurai I, et al. A comparative study of biapenem and imipenem/cilastatin for bacterial pneumonia [in Japanese]. Jpn J Chemother 1995; 43(1): 41–62

    Google Scholar 

  64. Kawada Y, Deguchi T, Kumamoto Y, et al. Comparative study on biapenem and imipenem/cilastatin in complicated urinary tract infection [in Japanese]. Chemotherapy 1994; 42(12): 1368–84

    Google Scholar 

  65. Kawada Y, Deguchi T, Tsukamoto T, et al. Comparative study on biapenem and imipenem/cilastatin in complicated urinary tract infections [in Japanese]. Jpn J Chemother 2000; 48(3): 218–32

    Google Scholar 

  66. Kawada Y, Deguchi T, Kawabe K, et al. Dose-finding study of biapenem in complicated urinary tract infections [in Japanese]. Jpn J Chemother 1999; 47(12): 852–62

    Google Scholar 

  67. Hara K, Baba S, Matsumoto F, et al. Clinical evaluation of biapenem in various infectious diseases [in Japanese]. Jpn J Antibiot 1999 Nov; 52(11): 629–60

    PubMed  CAS  Google Scholar 

  68. Baba S, Miyamoto N, Ichikawa G, et al. Laboratory and clinical findings on L-627 (biapenem) in otorhinolaryngological infections [in Japanese]. Jibi To Rinsho 1995; 41(No. 3): 495–509

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland, New Zealand

    Caroline M. Perry & Tim Ibbotson

Authors
  1. Caroline M. Perry
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tim Ibbotson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Caroline M. Perry.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Perry, C.M., Ibbotson, T. Biapenem. Drugs 62, 2221–2234 (2002). https://doi.org/10.2165/00003495-200262150-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200262150-00005

Keywords

Search

Navigation